The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Using integrative multiomics to explain myeloma progression and evolution of refractory disease
Ariosto Siqueira Silva, PhD, Moffitt Cancer Center, Tampa, FL, discusses work that aimed to study tumor evolution from progression to late refractory disease using integrative multiomics. Dr Silva mentions the two key epigenetic regulatory mechanisms identified by this research. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
